Eli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above an entry of $1,133.95
IBD 50
Eli Lilly Stock In A Buy Zone, Set To Ride The Peptide Wave
Licensing
11:40 AM ET 07/24/2026
Eli Lilly (LLY) stock is holding in a buy zone after the obesity drug leader made a major move to get its foot in the door of the hot wellness market. Meanwhile, the U.S. Food and Drug Administration's ongoing review of restrictions on seven peptides could have implications for the pharmaceutical giant. Shares hit their all-time high of 1,249.50 before…
Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. The stock has rallied nearly 36% from recent…
The maker of weight-loss drug Zepbound springs back into buy range.
Eli Lilly stock is in a buy zone above a pivot at 1,133.95 ahead of its second-quarter results, due on Aug. 5.
Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity…
The company's stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster…
